Core Viewpoint - Shanghai Yizhong (688091.SH) expects a significant increase in net profit for the year 2025, projecting a range of 60 million to 70 million yuan, representing a growth of 760.18% to 903.54% compared to the previous year [1] Group 1: Financial Performance - The anticipated net profit for 2025 is between 60 million and 70 million yuan [1] - This represents a substantial increase of 760.18% to 903.54% year-on-year [1] Group 2: Key Drivers - The primary reason for the performance change is the inclusion of the company's core product, paclitaxel polymer micelles, in the national medical insurance catalog for 2025 [1] - This inclusion is expected to significantly enhance market access and the number of patients using the product, leading to a notable increase in revenue and profit compared to 2024 [1]

格隆汇1月21日丨上海谊众(688091.SH)公布，公司预计2025年度实现归属于母公司所有者的净利润为 6000万元到7000万元；与上年同期相比，增长760.18%到903.54%。 公司预计2025年归属于母公司所有者的扣除非经常性损益的净利润为5600万元到6600万元；与上年同期 相比，增长1338.87%到1595.81%。 ...

证券代码：688091 证券简称：上海谊众 公告编号：2026-001 上海谊众药业股份有限公司 2025 年年度业绩预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 本期业绩预告情况 （一）业绩预告时间 2025 年 1 月 1 日—2025 年 12 月 31 日 （二）业绩预告情况 1、经财务部门初步测算，公司预计 2025 年度实现归属于母公司所有者的净利润为 6,000 万元到 7,000 万元；与上年同期相比，将增加 5,302 万元到 6,302 万元，同比增长 760.18%到 903.54%。 2、公司预计 2025 年归属于母公司所有者的扣除非经常性损益的净利润为 5,600 万 元到 6,600 万元；与上年同期相比，将增加 5,211 万元到 6,211 万元，同比增长 1,338.87% 到 1,595.81%。 （三） 本次业绩预告未经注册会计师审计。 三、 本期业绩变化的主要原因 公司核心产品注射用紫杉醇聚合物胶束（以下简称"紫杉醇胶束"）于 2025 年正式 纳 ...

Core Viewpoint - Shanghai Yizhong (688091.SH) expects a significant increase in net profit for the fiscal year 2025, projecting a range of 60 million to 70 million yuan, representing a growth of 760.18% to 903.54% compared to the previous year [2] Group 1: Financial Performance - The projected net profit for 2025 is between 60 million and 70 million yuan [2] - This represents a substantial increase of 760.18% to 903.54% year-over-year [2] Group 2: Business Drivers - The core product, paclitaxel micelles, is expected to be included in the national medical insurance catalog in 2025 [2] - The inclusion in the insurance catalog is anticipated to significantly increase market access and the number of patients using the product, leading to substantial revenue and profit growth [2]

Core Viewpoint - Shanghai Yizhong has announced an annual performance forecast, expecting a significant increase in net profit for 2025 due to the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance catalog [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 60 million to 70 million yuan for 2025, representing a year-on-year increase of 760.18% to 903.54% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 56 million and 66 million yuan, indicating a year-on-year growth of 1338.87% to 1595.81% [1] Product Impact - The significant growth in revenue and profit compared to 2024 is primarily driven by the market access and increased patient numbers for the company's core product, paclitaxel micelles, following its formal inclusion in the national medical insurance catalog in 2025 [1]

上海谊众公告，预计2025年度实现归属于母公司所有者的净利润为6000万元到7000万元，与上年同期相 比，增长760.18%到903.54%。公司核心产品注射用紫杉醇聚合物胶束于2025年正式纳入国家医保目 录，在市场准入与用药人数上大幅提高，带动了公司全年营收与利润相较于2024年显著增长。 ...

证券之星消息，1月19日化学制药板块较上一交易日下跌0.68%，上海谊众领跌。当日上证指数报收于 4114.0，上涨0.29%。深证成指报收于14294.05，上涨0.09%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 4.88 | 19.90% | 252.73万 | | 11.30亿 | | 600774 | 汉商集团 | 10.58 | 9.98% | 17.68万 | | 1.78亿 | | 688759 | 必贝特 | 52.00 | 8.02% | 5.92万 | | 3.07亿 | | 300086 | 康艺药业 | 11.09 | 7.88% | 62.96万 ﺎ | | 6.79亿 | | 300497 | 富祥药业 | 17.37 | 4.89% | 59.79万 | | 10.41亿 | | 002826 | 易明医药 | 19.14 | 4.65% | 11.34万 | | 2.17亿 | | ...

Market Overview - The chemical pharmaceutical sector increased by 1.77% on January 9, with Frontier Biotech leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Top Gainers in Chemical Pharmaceutical Sector - Frontier Biotech (688221) closed at 28.15, up 19.99% with a trading volume of 305,300 shares and a transaction value of 786 million [1] - Shanghai Yizhong (688091) closed at 60.84, up 17.29% with a trading volume of 119,400 shares and a transaction value of 688 million [1] - Yuekang Pharmaceutical (688658) closed at 31.79, up 17.13% with a trading volume of 200,400 shares and a transaction value of 586 million [1] - Lianhuan Pharmaceutical (600513) closed at 21.11, up 10.01% with a trading volume of 130,530 shares and a transaction value of 620 million [1] - Fuyuan Pharmaceutical (601089) closed at 30.27, up 9.99% with a trading volume of 108,600 shares and a transaction value of 31 million [1] Market Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 574 million from institutional investors, while retail investors saw a net inflow of 557 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional selling and retail buying [2] Individual Stock Capital Flow - Lianhuan Pharmaceutical (600513) had a net inflow of 180 million from institutional investors, but a net outflow of 68.68 million from retail investors [3] - Frontier Biotech (688221) saw a net inflow of 111 million from institutional investors, with retail investors experiencing a net outflow of 66.19 million [3] - Huahai Pharmaceutical (600521) had a net inflow of 89.80 million from institutional investors, while retail investors faced a net outflow of 60.06 million [3]

Core Viewpoint - The pharmaceutical sector is experiencing significant stock price increases, with notable gains in several companies, indicating positive market sentiment and potential investment opportunities [1]. Group 1: Company Performance - Weikang Pharmaceutical has seen its stock price rise by over 15% [1]. - Frontline Bio and Shanghai Yizhong have both increased by over 10% [1]. - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical are also experiencing upward trends in their stock prices [1].

Core Viewpoint - The innovative drug sector experienced a significant rally, with notable stock price increases among various companies [1] Group 1: Company Performance - Weikang Pharmaceutical saw its stock price rise by over 18% [1] - Qianfang Bio and Shanghai Yizhong both increased by more than 10% [1] - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical also experienced upward movement in their stock prices [1]